Skip to content

‘Scared to Death’: Nurses and Residents Confront Rampant Violence in Dementia Care Facilities

Clashes between residents — verbal, physical, and sexual — can be spontaneous and too unpredictable to prevent. But the chance of an altercation increases when memory care homes admit and retain residents they can’t manage, according to a KFF Health News examination of inspection and court records and interviews with researchers.

Faces of Medi-Cal

Medi-Cal’s Dental Care Gap: Getting a Tooth Pulled Is Easy — Much Harder To Get an Implant

California is among a growing number of states that offer dental benefits to low-income residents, but some lawmakers want the state to go further by covering more cleanings and costlier implants. Dentists and health experts worry the approach doesn’t address the root of the problem: Many providers don’t accept Medicaid.

The Politics Holding Back Medicaid Expansion in Some Southern States

Ten states have not expanded Medicaid, leaving 1.5 million people ineligible for the state and federal insurance program and also unable to afford private insurance. Seven of those states are in the South, where expansion efforts may have momentum but where lawmakers say political polarization is holding them back.

Podcast

KFF Health News' 'What the Health?': The Walz Record

Vice President Kamala Harris this week officially became the Democratic nominee for president and named Minnesota governor and former U.S. congressman Tim Walz as her running mate. Meanwhile, a new study finds the number of abortions taking place since the overturn of “Roe v. Wade” continued to rise into early this year, despite the imposition of abortion bans around the country. Sandhya Raman of CQ Roll Call and Shefali Luthra of The 19th join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more.

How Little Denmark Got Homegrown Giant Novo Nordisk To Lower Ozempic Prices

As Congress pushes for Medicare to cover payment for anti-obesity drugs, Denmark — Ozempic maker Novo Nordisk’s home — has limited coverage of the drug after cost overruns “emptied all the money boxes in the entire public health system.”